Potential for misdiagnosis in community-acquired PET scans for dementia
- PMID: 24195019
- PMCID: PMC3787114
- DOI: 10.1212/CPJ.0b013e318296f2df
Potential for misdiagnosis in community-acquired PET scans for dementia
Abstract
We reviewed records of patients seen in a tertiary Neurobehavior Clinic to identify those who had community-acquired PET scans as part of their dementia diagnostic evaluation with the goal of assessing factors influencing diagnostic accuracy. We compared outside radiologist PET diagnoses to our consensus clinical diagnosis and collected data regarding clinical variables, ordering reasons, and specialties of interpreting and ordering physicians. Among 1,580 total patients seen in our clinic, 46 met our inclusion criteria. There was disagreement between outside diagnosis based on PET and our consensus diagnosis in 65% (n = 30) of patients. Community-acquired PET scans may have lower diagnostic value in dementia evaluation than suggested by prior research and may be associated with significant risks including misdiagnosis with an incurable neurodegenerative disease.
Similar articles
-
Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies.Cochrane Database Syst Rev. 2015 Jan 30;1(1):CD010633. doi: 10.1002/14651858.CD010633.pub2. Cochrane Database Syst Rev. 2015. PMID: 25632881 Free PMC article. Review.
-
Diagnostic impact of [18F]flutemetamol PET in early-onset dementia.Alzheimers Res Ther. 2017 Jan 17;9(1):2. doi: 10.1186/s13195-016-0228-4. Alzheimers Res Ther. 2017. PMID: 28093088 Free PMC article. Clinical Trial.
-
Amyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [18F]FDG PET.Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):312-323. doi: 10.1007/s00259-018-4111-3. Epub 2018 Aug 10. Eur J Nucl Med Mol Imaging. 2019. PMID: 30094462 Free PMC article.
-
Impact of molecular imaging on the diagnostic process in a memory clinic.Alzheimers Dement. 2013 Jul;9(4):414-21. doi: 10.1016/j.jalz.2012.07.003. Epub 2012 Nov 16. Alzheimers Dement. 2013. PMID: 23164552 Clinical Trial.
-
Positron Emission Tomography, Single Photon Emission Computed Tomography, Computed Tomography, Functional Magnetic Resonance Imaging, and Magnetic Resonance Spectroscopy and for the Diagnosis and Management of Alzheimer’s Dementia [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2004 Apr 30. Rockville (MD): Agency for Healthcare Research and Quality (US); 2004 Apr 30. PMID: 25879122 Free Books & Documents. Review.
Cited by
-
AITeQ: a machine learning framework for Alzheimer's prediction using a distinctive five-gene signature.Brief Bioinform. 2024 May 23;25(4):bbae291. doi: 10.1093/bib/bbae291. Brief Bioinform. 2024. PMID: 38877887 Free PMC article.
-
Analysis and Characterization of the Extracellular Vesicles Released in Non-Cancer Diseases Using Matrix-Assisted Laser Desorption Ionization/Mass Spectrometry.Int J Mol Sci. 2024 Apr 19;25(8):4490. doi: 10.3390/ijms25084490. Int J Mol Sci. 2024. PMID: 38674075 Free PMC article. Review.
-
Biomarkers for parkinsonian disorders in CNS-originating EVs: promise and challenges.Acta Neuropathol. 2023 May;145(5):515-540. doi: 10.1007/s00401-023-02557-1. Epub 2023 Apr 4. Acta Neuropathol. 2023. PMID: 37012443 Free PMC article. Review.
-
High-throughput epitope profiling of antibodies in the plasma of Alzheimer's disease patients using random peptide microarrays.Sci Rep. 2019 Mar 14;9(1):4587. doi: 10.1038/s41598-019-40976-x. Sci Rep. 2019. PMID: 30872784 Free PMC article.
-
An Algorithm for Preclinical Diagnosis of Alzheimer's Disease.Front Neurosci. 2018 Apr 30;12:275. doi: 10.3389/fnins.2018.00275. eCollection 2018. Front Neurosci. 2018. PMID: 29760644 Free PMC article. Review.
References
-
- Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143–1153 - PubMed
-
- Medicare National Coverage Determinations Manual: Chapter 1, Part 4 (Sections 200–310.1)—Coverage Determinations. Centers for Medicare and Medicaid Services. Available at: www.cms.gov/manuals/downloads/ncd103c1_Part4.pdf. Accessed January 5, 2012.
-
- Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain A J Neurol 2007;130:2616–2635 - PubMed
-
- Ishii K, Sakamoto S, Sasaki M, et al. Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med 1998;39:1875–1878 - PubMed
-
- Diehl-Schmid J, Grimmer T, Drzezga A, et al. Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET study. Neurobiol Aging 2007;28:42–50 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous